187 related articles for article (PubMed ID: 22566197)
21. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
[TBL] [Abstract][Full Text] [Related]
22. Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 May; 40(5):e278-81. PubMed ID: 25783505
[TBL] [Abstract][Full Text] [Related]
23. Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 Apr; 40(4):317-21. PubMed ID: 25674857
[TBL] [Abstract][Full Text] [Related]
24. Nephrotoxicity after PRRT - still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y/177Lu-DOTATATE.
Kunikowska J; Królicki L; Sowa-Staszczak A; Pawlak D; Hubalewska-Dydejczyk A; Mikołajczak R
Endokrynol Pol; 2013; 64(1):13-20. PubMed ID: 23450442
[TBL] [Abstract][Full Text] [Related]
25. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
[TBL] [Abstract][Full Text] [Related]
26. Complete Response to 177 Lu-DOTATATE PRRT in a 9-Year-Old Child With Metastatic Carotid Body Paraganglioma.
Yadav MP; Raju S; Ballal S; Bal C
Clin Nucl Med; 2024 Jan; 49(1):e33-e34. PubMed ID: 37976428
[TBL] [Abstract][Full Text] [Related]
27. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
Ianniello A; Sansovini M; Severi S; Nicolini S; Grana CM; Massri K; Bongiovanni A; Antonuzzo L; Di Iorio V; Sarnelli A; Caroli P; Monti M; Scarpi E; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1040-6. PubMed ID: 26611427
[TBL] [Abstract][Full Text] [Related]
28. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
[TBL] [Abstract][Full Text] [Related]
29. Additional hepatic
Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
[TBL] [Abstract][Full Text] [Related]
30. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma.
Kunst HP; Rutten MH; de Mönnink JP; Hoefsloot LH; Timmers HJ; Marres HA; Jansen JC; Kremer H; Bayley JP; Cremers CW
Clin Cancer Res; 2011 Jan; 17(2):247-54. PubMed ID: 21224366
[TBL] [Abstract][Full Text] [Related]
31. Peptide receptor radionuclide therapy with (177)Lu DOTATATE in a case of recurrent carotid body paraganglioma with spinal metastases.
Gupta SK; Singla S; Karunanithi S; Damle N; Bal C
Clin Nucl Med; 2014 May; 39(5):440-1. PubMed ID: 24217545
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Bal C
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1595-1606. PubMed ID: 34837103
[TBL] [Abstract][Full Text] [Related]
33. Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.
Kunikowska J; Bajera A; Sawicka M; Czwarnowski P; Pawłowicz B; Aksamit D; Pawlak D; Królicki L
Nucl Med Rev Cent East Eur; 2013; 16(2):70-4. PubMed ID: 24068636
[TBL] [Abstract][Full Text] [Related]
34. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
Gupta SK; Singla S; Bal C
Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
[TBL] [Abstract][Full Text] [Related]
35. Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy.
Makis W; McCann K; Buteau FA; McEwan AJ
Clin Nucl Med; 2015 Aug; 40(8):663-6. PubMed ID: 25546219
[TBL] [Abstract][Full Text] [Related]
36. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
37. Peptide Receptor Radionuclide Therapy with
Ramesh S; Kudachi S; Basu S
J Nucl Med Technol; 2018 Sep; 46(3):292-294. PubMed ID: 29884687
[TBL] [Abstract][Full Text] [Related]
38. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
Makis W; McCann K; Riauka TA; McEwan AJ
Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569
[TBL] [Abstract][Full Text] [Related]
39. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature.
Tang CYL; Chua WM; Huang HL; Lam WW; Loh LM; Tai D; Ong SYK; Yan SX; Loke KSH; Ng DC; Tham WY
J Neuroendocrinol; 2023 Dec; 35(12):e13349. PubMed ID: 37937484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
